Clinical Trials Logo

Clinical Trial Summary

This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with a PD-1 inhibitor in subjects with advanced solid tumors.


Clinical Trial Description

This Phase 1-2 study is designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805, a fully human IgG1 antibody that binds specifically to CD163, in subjects with advanced solid tumors. The study consists of four parts: - Part A: a dose-escalation phase to determine the maximum-tolerated dose (MTD) or maximum achievable dose and the recommended phase 2 dose (RP2D) of OR2805 in a maximum of approximately 20 subjects. - Part B: a monotherapy expansion phase of up to approximately 40 subjects in each of 4 select tumor types at the RP2D to determine preliminary anti-tumor activity and further characterize safety. - Part C: a mini-dose-escalation at 2 doses of OR2805 in combination with a PD-1 inhibitor followed by a combination expansion cohort of up to approximately 40 subjects in each of 2 tumor types to determine the safety and preliminary anti-tumor activity of OR2805 in combination with a PD-1 inhibitor. - Part D: a biology cohort of up to approximately 20 subjects at the RP2D to determine mechanism of action and potential predictors of response and pharmacodynamics in subjects not eligible for either Part B or C. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05094804
Study type Interventional
Source OncoResponse, Inc.
Contact Kate Harrop
Phone 425-420-0749
Email [email protected]
Status Recruiting
Phase Phase 1/Phase 2
Start date September 9, 2021
Completion date August 15, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Enrolling by invitation NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery
Completed NCT04281953 - Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
Recruiting NCT02478931 - Study of Personalized Cancer Therapy to Determine Response and Toxicity
Recruiting NCT04087252 - An Immunogenic Personal Neoantigen Vaccine for Cancer Treatment Phase 1